Skip to main content

News

Upadacitinib FDA Approved for Ankylosing Spondylitis

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

$30 Billion and Counting (4.29.2022)

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Prolonged TNF Inhibitor Use Delays Sacroiliac Progression

While tumour necrosis factor inhibitors (TNFi) have been shown to alter/retard X-ray outcomes in peripheral inflammatory arthritis, the inhibitor effects of TNFi on axial skeletal progression in spondylitis has been difficult to prove, owing to difficulties in study design, identifying best cohorts and a presumed slower rate of change in the spine. 

Intraarticular Steroids in Hip Osteoarthritis - Do They Work?

The efficacy of ultrasound guided intra-articular hip injection of corticosteroid in adult hip osteoarthritis (HOA) was shown to be effective when added to conventional current treatment. But was this a clinically meaningful outcome?

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Biologics for JIA? Not So Fast, Say Insurers

MedPage Today

It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.

Arthritis Predicts Hepatic Fibrosis in Hemochromatosis

Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis. 

Pre-exposure Prophylaxis for COVID-19 (4.22.22)

Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD). Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102 countries was analyzed.

Evusheld as Protective Therapy in High Risk COVID-19 Patients

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

TNR - Controversies in PsA

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.

The PsA Expert panelists included:

Faith in Exercise Benefit Boosts Actual Benefit in SpA

MedPage Today

Patients with axial spondyloarthritis (SpA) got more bang for their exercise buck in a randomized trial when they had good opinions about their workout program, with better persistence with exercise at 1 year relative to a control group, researchers said.

×